The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumocystis jiroveci pneumonia
Publications
Grigoropoulos I, Thomas K, Christoforou P, Fanidi I, Papavdi M, Kyriakou F, Deutsch M, Pirounaki M, Vassilopoulos D
Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Mediterranean journal of rheumatology 2019 Sep;30;167-170 — 2019 Sep — 167-170
Atypical presentation of pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation.
BMC rheumatology 2018;2;34 — 2018 — 34